Catalyst
Slingshot members are tracking this event:
VBL Therapeutics (VBLT) presents data demonstrating ex-vivo activity of its investigational anti-MOSPD2 (motile sperm domain-containing protein 2) mAbs in patients with relapsing-remitting and progressive multiple sclerosis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VBLT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 11, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Relapsing-remitting Multiple Sclerosis, Progressive Multiple Sclerosis
